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Vascular Medicine
Use and Outcomes Associated With Bridging
During Anticoagulation Interruptions in Patients With
Atrial Fibrillation
Findings From the Outcomes Registry for Better Informed Treatment
of Atrial Fibrillation (ORBIT-AF)
Benjamin A. Steinberg, MD, MHS; Eric D. Peterson, MD, MPH; Sunghee Kim, PhD;
Laine Thomas, PhD; Bernard J. Gersh, MBChB, DPhil; Gregg C. Fonarow, MD;
Peter R. Kowey, MD; Kenneth W. Mahaffey, MD; Matthew W. Sherwood, MD, MHS; Paul Chang,
MD; Jonathan P. Piccini, MD, MHS; Jack Ansell, MD; on behalf of the Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients*
Background—Temporary interruption of oral anticoagulation for procedures is often required, and some propose using
bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical
practice are unknown.
Methods and Results—The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry is a
prospective, observational registry study of US outpatients with atrial fibrillation. We recorded incident temporary interruptions
of oral anticoagulation for a procedure, including the use and type of bridging therapy. Outcomes included multivariableadjusted rates of myocardial infarction, stroke or systemic embolism, major bleeding, cause-specific hospitalization, and death
within 30 days. Of 7372 patients treated with oral anticoagulation, 2803 overall interruption events occurred in 2200 patients
(30%) at a median follow-up of 2 years. Bridging anticoagulants were used in 24% (n=665), predominantly low-molecularweight heparin (73%, n=487) and unfractionated heparin (15%, n=97). Bridged patients were more likely to have had prior
cerebrovascular events (22% versus 15%; P=0.0003) and mechanical valve replacements (9.6% versus 2.4%; P<0.0001);
however, there was no difference in CHA2DS2-VASc scores (scores ≥2 in 94% versus 95%; P=0.5). Bleeding events were
more common in bridged than nonbridged patients (5.0% versus 1.3%; adjusted odds ratio, 3.84; P<0.0001). The incidence
of myocardial infarction, stroke or systemic embolism, major bleeding, hospitalization, or death within 30 days was also
significantly higher in patients receiving bridging (13% versus 6.3%; adjusted odds ratio, 1.94; P=0.0001).
Conclusions—Bridging anticoagulation is used in one quarter of anticoagulation interruptions and is associated with higher
risk for bleeding and adverse events. These data do not support the use of routine bridging, and additional data are needed
to identify best practices concerning anticoagulation interruptions.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT01165710.
(Circulation. 2015;131:488-494. DOI: 10.1161/CIRCULATIONAHA.114.011777.)
Key Words: anticoagulants ◼ atrial fibrillation ◼ outcome assessment (health care)

O

ral anticoagulation (OAC) significantly reduces the
risk of stroke in patients with atrial fibrillation (AF).
However, many AF patients on long-term anticoagulation undergo procedures that require temporary interruption of OAC.1,2 Some have advocated that patients receive

short-acting anticoagulants during these temporary interruptions to “bridge” the patient and to potentially reduce the risk
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of embolic events during the interruption.3 Although guidelines have been published on when and how to initiate bridging therapy,4 they are based on limited data. Thus, it remains
unclear whether patients who temporarily interrupt their anticoagulation should receive bridging anticoagulation.
We assessed the incidence of temporary interruption of OAC for
procedures among a national outpatient AF registry. We specifically
examined causes for the interruption of anticoagulation, the patterns
of use of bridging anticoagulation agents (relative to underlying risk
and current guidelines), and the outcomes among patients who were
bridged compared with patients who were not bridged.

Methods
The Outcomes Registry for Better Informed Treatment of Atrial
Fibrillation (ORIBT-AF) is a national, community-based registry of
outpatients with AF. Eligible patients were enrolled by a nationally
representative sample of primary care, cardiology, or electrophysiology sites. An adaptive design was used to ensure heterogeneity of
practice type and geography. Study coordination was managed by
the Duke Clinical Research Institute. Major inclusion criteria were
age of ≥18 years and ECG-documented AF that was not attributable
to a reversible cause, and follow-up was to a maximum of 3 years.
The ORBIT-AF registry has been described in detail previously.5 The
present analysis includes patient data out to 2 years of follow-up.
Data collection was derived primarily from the patients’ medical
records and included demographics, medical history, and AF history
at baseline. Additionally, at baseline and every 6 months, investigators recorded medical and surgical therapies, vital signs, laboratory
measurements, and echocardiographic data. The collection of medication data included the use and monitoring of OAC therapies. Sites
were also instructed to enter which OAC treatment was used, as well
as values for international normalized ratio monitoring when applicable. At each follow-up, investigators were queried as to whether the
patient temporarily interrupted OAC to undergo a procedure. Only
interruptions for procedures were recorded; interruptions as a result
of bleeding or other reasons are not captured. All medical management around the procedure was guided entirely by the patient’s treatment team. For such interruptions, we collected the date and type of
procedure, use of bridging anticoagulant (defined as an anticoagulant
temporarily administered in place of long-term therapy for the purpose of stroke prevention before, during, or after the periprocedural
period), and adverse events occurring during the interruption (bleeding event, thrombotic event, or other event; no further specification
was reported). Type of procedure was categorized as cardiac catheterization, catheter ablation, endoscopy (gastrointestinal, bronchoscopic, or genitourinary), cardiac surgery, noncardiac surgery (not
further specified), device implantation, dental procedures, or other
(not further specified). Bridging anticoagulant was categorized as
low-molecular-weight heparin (LMWH), unfractionated heparin
(UFH), fondaparinux, or other (not further specified).
Separately at each follow-up, investigators recorded the incidence
and dates of any adverse events, including death, cause-specific hospitalization (cardiovascular, bleeding, or other, as determined by the
investigator), incident heart failure, myocardial infarction, stroke or
systemic embolism (adjudicated by the coordinating center from
primary source documentation), or major bleeding as defined by the
International Society of Thrombosis and Haemostasis criteria.6

Analyzing Temporary Interruptions
The present analysis included only patients on OAC at baseline who
had at least 1 follow-up visit. The study population was subsequently
divided by incidence of interruption during follow-up: none versus any
(≥1). The baseline characteristics of these patients were compared.
Subsequently, all interruption events were queried for the type of
procedure requiring interruption and the use of bridging anticoagulant. Additionally, the use of bridging anticoagulation was compared
among high-risk subgroups. Among patients using warfarin, time to
resumption of therapeutic international normalized ratio (≥2) was

calculated. The use of bridging anticoagulation in the subgroup of
patients receiving dabigatran was also described.
Adverse events occurring during the interruption of long-term
anticoagulation (bleeding, thrombotic, or other [not further detailed])
are described and stratified by the use of any bridging anticoagulant
versus none. The incidence and timing of adverse events occurring
within 30 days after the date of the procedure for which there was an
interruption are also described (and may overlap with those occurring
during interruption); these include cause-specific hospitalization and
the composite of myocardial infarction, stroke, major bleeding, hospitalization, or death. The association of bridging with adverse events
was assessed in a multivariable model of the composite outcome.

Statistical Methods
Comparisons between groups with no interruption and groups with any
interruption are performed at the patient level. Comparisons between
procedure types, bridging anticoagulant, and adverse events are performed at the interruption level (a patient may have had >1 interruption during follow-up). In univariate analyses, categorical variables are
presented as frequencies and percentages, and differences between 2
groups are assessed by the χ2 test. Continuous variables are presented
as median (quartiles 1–3) or mean (standard deviation), and differences
between 2 groups are assessed by the Wilcoxon rank-sum test.
In analysis of adverse events within 30 days after interruption, multiple interruption events from the same patient were included unless the
interruptions occurred within 30 days of a prior interruption. However,
interruption events were excluded if the date was missing. To identify the association between the use of any bridging anticoagulant
and adverse events, a multivariable model was developed. Covariates
included age, estimated glomerular filtration rate, sex, prior cerebrovascular events, the presence of significant valvular disease or prior
mechanical valve replacement, prior gastrointestinal bleeding, the
presence of congestive heart failure, type of AF at baseline (new onset,
paroxysmal, persistent, longstanding persistent), left atrial diameter
size, patient level of education, CHADS2 score, the procedure requiring interruption (with noncardiac surgery as the referent), and type of
OAC at baseline (warfarin versus dabigatran; neither rivaroxaban nor
apixaban was used in this cohort). The outcomes examined included
any bleeding events (major bleeding or bleeding hospitalization); cardiovascular events (stroke, systemic embolism, myocardial infarction,
or cardiovascular hospitalization); and the composite of any myocardial infarction, stroke or systemic embolism, any hospitalization,
or death, all within 30 days after the date of the procedure requiring
interruption. Adjusted odds ratios (ORs) were calculated from logistic regression with the generalized estimating equation, which also
accounted for correlations within the same patient.
The ORBIT-AF registry was approved by the institutional review
board of Duke University, and each site received institutional review
board approval subject to local requirements. All patients signed
written, informed consent, and analyses of the aggregate, deidentified
data were performed by the Duke Clinical Research Institute using
SAS software (version 9.3, SAS Institute, Cary, NC).

Results
The overall ORBIT-AF population included 10 132 patients
from 176 sites; 9642 patients had at least 1 follow-up visit.
Excluding patients not on OAC at baseline (n=2270) yielded
a final study cohort of 7372 patients. The median follow-up
duration was 24 months. Overall, there were 2803 reported
interruptions, the majority in noncardiac surgery (n=746,
27%), other procedures (n=712, 25%), and endoscopy (n=504
18%). Overall, 2138 interruptions (76%) did not use bridging anticoagulation, whereas 665 (24%) did. Distribution of
bridging use by procedure is shown in the Figure.
Among the 665 interruption events that involved bridging
anticoagulation, LMWH was used in 487 (73%), UFH in 97
(15%), fondaparinux in 7 (1.1%), and another anticoagulant in
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Figure. Proportion of interruptions involving anticoagulant
bridging by procedure. Endoscopy includes gastrointestinal,
genitourinary, or bronchoscopic. cath indicates catheterization;
and CV, cardiovascular.

76 (11%). Twenty-three interruptions involving bridging were
in patients treated with dabigatran at baseline: 12 used LMWH,
6 used UFH, and 5 used other agents (none used fondaparinux).
A comparison of baseline characteristics between patients
with no interruption (n=5172, 70%) and those with ≥1 interruption during follow-up (n=2200, 30%) stratified by bridging
use is shown in Table 1. Compared with patients who did not
have any interruption, those experiencing at least 1 interruption were slightly younger (median age, 75 versus 76 years;
P=0.0002), more likely white (92% versus 89%; P=0.005),
and less likely to have new-onset AF (2.6% versus 4.3%;
P=0.0001) and had higher median calculated creatinine clearance (71 versus 69 mL·min−1·1.72 m−2; P=0.002).7 Rates of
prior coronary vascular or cerebrovascular disease, as well as
mean CHADS2 scores, were all similar (P=NS for each). Of
patients with at least 1 interruption, patients with any bridging
interruption were statistically younger (median age, 74 versus
75 years; P=0.009) and were more likely to have congestive
heart failure (44% versus 34%; P<0.0001), prior cerebrovascular events (22% versus 15%; P=0.0003), any valve disease
(34% versus 27%; P=0.0006), and prior mechanical valve
(9.6% versus 2.4%; P<0.0001) compared with patients who
had at least 1 interruption but none with bridging. Baseline
OAC also differed significantly (dabigatran in 3.7% versus
6.8%; P=0.02). Although mean CHADS2 (2.53 versus 2.34;
P=0.004) and CHA2DS2-VASc (4.25 versus 4.03; P=0.01)
scores were higher in bridged patients, there were no differences in rates of CHADS2 score ≥2 (78% versus 76%; P=0.4)
or CHA2DS2-VASc score ≥2 (94% versus 95%; P=0.5). Use
of additional antiplatelet therapy was similar for concomitant
single antiplatelet (39% versus 36%) and dual antiplatelet therapy (3.0% versus 2.2%; P=0.2 across antiplatelet categories).
Among patients treated with warfarin who had at least 1
follow-up international normalized ratio after the procedure
(n=1452), time to the achievement of the therapeutic range (first
international normalized ratio ≥2) after the procedure was significantly shorter for interruptions with bridging compared with
those without bridging (median, 17 versus 23 days; P<0.001).8

Unadjusted rates of individual outcomes during and after interruption are shown in Table 2. Events during interruption were
relatively infrequent overall. Event rates were higher for interruptions in which bridging anticoagulation was used, including any adverse event during interruption (5.3% versus 2.8%;
P=0.01), major bleeding (3.6% versus 1.2%; P=0.0007),
bleeding hospitalization (2.2% versus 0.7%; P=0.006), and
cardiovascular hospitalization (4.2% versus 2.2%; P=0.02).
Event counts and rates across different procedure types stratified by bridging are shown in Table 3.
The association between bridging and adverse events persisted in multivariate-adjusted analysis (Table 4): The use of
bridging anticoagulation during interruption was significantly
associated with an increase in bleeding events (adjusted OR,
3.84 for major bleeding or bleeding hospitalization; 95% confidence interval, 2.07–7.14; P<0.0001) and showed a trend
toward increased cardiovascular events (adjusted OR, 1.62;
95% confidence interval, 0.95–2.78; P=0.07). Overall, bridging
was associated with an increased risk of adverse events, including the composite of myocardial infarction, bleeding, stroke
or systemic embolism, hospitalization, or death within 30
days (adjusted OR 1.94; 95% confidence interval, 1.38–2.71;
P=0.0001). The procedure for which the patient required interruption appeared to minimally influence composite adverse outcomes (P=0.2 across all procedures); however, adverse events
were significantly less common for dental procedures (adjusted
OR, 0.19 versus noncardiac surgery; 95% confidence interval,
0.06–0.63, Ppairwise=0.0063). Baseline anticoagulant (warfarin
versus dabigatran) was not significantly associated with outcomes after temporary interruption in the adjusted model.
In a sensitivity analysis that included baseline concomitant
antiplatelet use (none, single, double), a consistent, significant
association remained between bridging and adverse outcome.

Discussion
There are 3 major findings from this study. First, interruptions
of OAC are common in contemporary patients with AF in
clinical practice, often for cardiac procedures and noncardiac
surgery, as well as for minimally invasive procedures. Second,
in those temporary interruptions, bridging anticoagulation was
used in approximately one quarter of patients, and the decision to use bridging appears to be guided by patient factors
related to bleeding or thromboembolic risk. Finally, we found
that the use of bridging anticoagulation was significantly associated with higher overall bleeding and adverse event rates.
The rate of bridging anticoagulation was higher than that
reported in contemporary trials.9 Patients with prior cerebrovascular events, those with mechanical valves, and patients receiving warfarin (compared with dabigatran) were more likely
to receive bridging anticoagulation, as would be expected.
Additionally, bridging varied by type of procedure. These data
generally reflect the limited guideline support for bridging,
specifically that the decision for bridging in moderate- or highrisk patients should be patient and procedure specific and that
bridging in patients at low risk of thromboembolism should be
avoided.4 Furthermore, the guidelines recommend more conservative management of bridging medications and call attention to scenarios in which OAC could be continued without
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Table 1. Baseline Demographics, Medical History, and Laboratory Studies by Incidence of Temporary Interruption
No Temporary
Interruption
(n=5172)

Age, y
Female, %

≥1 Temporary Interruptions
(n=2200)
Patients With ≥1
Interruptions, None With
Bridging (n=1608)

Patients With
≥1 Interruptions With
Bridging (n=592)

P Value,
No Bridging
Versus Bridging

76 (68–82)

75 (68–81)

74 (67–80)

0.009

43

41

42

Race/ethnicity, %

0.1

 White

89

92

 Black

5.0

3.5

5

 Hispanic

4.6

3.7

2.7

 Other

1.5

1.2

0.5

91

 New onset

4.3

2.7

2.2

 Paroxysmal

46

46

48

 Persistent

19

16

17

AF type, %

 Long-standing persistent

0.7

0.5

31

35

32

CHADS2 score, mean (SD)

2.4 (1.3)

2.34 (1.21)

2.53 (1.31)

0.004

CHA2DS2-VASc score, mean (SD)

4.0 (1.7)

4.03 (1.62)

4.25 (1.74)

0.01

2.78 (1.89)

2.74 (1.94)

2.72 (1.95)

0.9

Prior cerebrovascular event, %

17

15

22

Coronary artery disease, %

36

36

41

0.05

Congestive heart failure, %

34

34

44

<0.0001

Significant valve disease, %

27

27

34

0.0006

ATRIA score, mean (SD)

0.0003

Moderate/severe mitral stenosis, %

1.7

1.1

2.5

0.01

Prior mechanical valve replacement, %

3.6

2.4

9.6

<0.0001

92

91

91

Prior GI bleeding, %
 Never

0.97

 >6 mo prior

6.9

1.4

1.5

 ≤6 mo prior

0.8

7.3

7.1

 Warfarin

93

93

96

 Dabigatran

6.5

6.8

3.7

Most recent INR before the procedure,
mean (SD)

…

2.34 (0.76)

2.28 (0.71)

Percentage of time with INR 2–3 before
the procedure, %*

…

67

62

0.0002

Baseline oral anticoagulant, %

0.02

0.3

Concomitant antiplatelet, %†
 Aspirin

36

36

38

0.4

 Clopidogrel

4.5

4.2

6.9

0.01

 Prasugrel

0.03

0.06

0

0.5

Calculated creatinine
clearance, mL·min−1·1.73 m−2‡

69 (49–95)

71 (54–97)

70 (51–96)

0.3

LVEF, %

55 (50–60)

55 (50–60)

55 (45–60)

<0.001

Values are presented as median (interquartile range) when appropriate. AF indicates atrial fibrillation; ATRIA, Anticoagulation and Risk Factors
in Atrial Fibrillation; GI, gastrointestinal; INR, international normalized ratio; and LVEF, left ventricular ejection fraction.
*As calculated using the Rosendaal et al8 method.
†Including aspirin, clopidogrel, or prasugrel; no patient was on ticagrelor.
‡As calculated by the Cockcroft-Gault7 formula.

interruption (eg, dental procedures). Although this appears to
demonstrate improvement in the previously described practice variability,10 room for further improvement remains, as
indicated by the data in this study. Bridging anticoagulation

appeared to be used more commonly than the guidelines would
suggest. For example, we observed that a significant number
of OAC interruptions were for dental procedures (n=239, 9%
of all interruptions), and 8% of these temporary interruptions
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Table 2. Unadjusted Outcomes During and After Temporary
Interruption of OAC

Table 4. Adjusted 30-Day Outcomes by Use of Bridging
Anticoagulation

Overall
(n=2280),
% (n)

No Bridging
(n=1766),
% (n)

Bridging
(n=514),
% (n)

Unadjusted, % (n)
P Value

Any adverse event during
interruption

3.4 (77)

2.8 (50)

5.3 (27)

0.01

 Bleeding event

2.2 (50)

1.8 (31)

3.7 (19)

0.02

 Thrombotic event

0.6 (13)

0.5 (9)

0.8 (4)

0.5

Cardiovascular
events†

 Other adverse event

0.6 (14)

0.6 (10)

0.8 (4)

0.6

Bleeding events‡ 1.3 (22)

5.0 (25) <0.0001 3.84 (2.07–7.14) <0.0001

Overall
composite§

13 (64) <0.0001 1.94 (1.38–2.71)

Events within 30 d after the procedure requiring interruption*
 Myocardial infarction

0.2 (5)

0.2 (4)

0.2 (1)

0.9

 Stroke or systemic
embolism

0.4 (8)

0.3 (5)

0.6 (3)

0.3

 Major bleeding

1.7 (38)

1.2 (20)

3.6 (18)

0.0007

  Cardiovascular

2.7 (59)

2.2 (38)

4.2 (21)

0.02

  Bleeding

1.0 (23)

0.7 (12)

2.2 (11)

0.006

  Other

3.1 (69)

2.8 (49)

4.0 (20)

0.2

 Death

0.2 (4)

0.2 (3)

0.2 (1)

0.9

 Hospitalization

OAC indicates oral anticoagulation.
*Denominators exclude interruptions missing date or those that occurred
within 30 days of a previous interruption (n=2227 overall, 1724 without
bridging, 503 with bridging). Events within 30 days of the procedure requiring
interruption may overlap with those during interruption.

involved the use of a bridging anticoagulant. Furthermore, there
were excess adverse events in bridged patients undergoing specific procedures (eg, catheter ablation, endoscopy), indicating
particularly unfavorable risk in these cases. Such management
may contribute to worse clinical outcomes overall, and our data
do not support the routine use of bridging in AF patients requiring temporary interruption of anticoagulation.
Our data show that the risks associated with interruptions
and the risk of bridging during them are not limited to the
Table 3. Adverse Events Within 30 Days by Procedure Type
and Bridging Anticoagulation
Cardiovascular
Events, n (%)*
No Bridging
(n=1724)
Catheterization/PCI
Catheter ablation
Endoscopic
procedure
Cardiac surgery
Noncardiac surgery

Bleeding
Events, n (%)†

Bridging
(n=503)

No Bridging
(n=1724)

9/139 (6.5)

3/65 (4.6)

2/139 (1.4)

1/66 (1.5)

5/41 (12.2)

1/66 (1.5)

9/343 (2.6)

2/64 (3.1)

5/343 (1.5)

Bridging
(n=503)
1/65 (1.5)
0/41 (0)
5/64 (7.8)

3/48 (6.3)

2/28 (7.1)

2/48 (4.2)

2/28 (7.1)

6/410 (1.5)

2/149 (1.3)

5/410 (1.2)

12/149 (8.1)

Device implantation

9/139 (6.5)

2/38 (5.3)

0/139 (0)

0/38 (0)

Dental work

1/166 (0.6)

0/16 (0)

0/166 (0)

0/16 (0)

Other

5/413 (1.2)

7/102 (6.9)

7/413 (1.7)

5/102 (4.9)

Excluding interruptions missing a date or those that occurred within 30 days
of a previous interruption. PCI indicates percutaneous coronary intervention.
*Includes stroke, systemic embolism, myocardial infarction, or cardiovascular
hospitalization within 30 days of the procedure requiring interruption.
†Includes major bleeding or bleeding hospitalization within 30 days of the
procedure requiring interruption.

Adjusted*

No Bridging Bridging
(n=1724) (n=503) P Value
2.5 (43)

6.3 (108)

4.6 (23)

0.02

Adjusted OR
(95% CI),
Bridging Versus
No Bridging

P Value

1.62 (0.95–2.78)

0.07

0.0001

Denominators exclude interruptions missing a date or those that occurred
within 30 days of a previous interruption. Events within 30 days of the procedure
requiring interruption may overlap with those during interruption. CI indicates
confidence interval; and OR, odds ratio.
*Adjustment model covariates included age, estimated glomerular filtration rate,
sex, prior cerebrovascular events, the presence of significant valvular disease or
prior mechanical valve replacement, prior gastrointestinal bleeding, the presence
of congestive heart failure, type of atrial fibrillation at baseline (new onset,
paroxysmal, persistent, long-standing persistent), left atrial diameter size, patient
level of education, CHADS2 score, procedure requiring interruption (with noncardiac
surgery as the referent), and type of oral anticoagulation at baseline (warfarin
versus dabigatran; neither rivaroxaban nor apixaban was used in this cohort).
†Includes stroke, systemic embolism, myocardial infarction, or cardiovascular
hospitalization within 30 days of the procedure requiring interruption.
‡Includes major bleeding or bleeding hospitalization within 30 days of the
procedure requiring interruption.
§Includes the composite of stroke, myocardial infarction, major bleeding,
hospitalization, or death within 30 days of the procedure requiring interruption.

periprocedural period. Adverse events in patients interrupting
OAC persist as late as 30 days and include bleeding events,
thrombotic events, and recurrent hospitalizations. Although the
use of bridging has been shown to be safe in closely controlled
clinical trials,3,11 outcomes in the community, where protocols
are often absent or inconsistent, have been more limited. They
included heterogeneous patient cohorts anticoagulated for a
variety of indications, and only bleeding and thromboembolic
outcomes were reported.1,2
The most recent US national guidelines highlight the
dearth of evidence for the practice12; furthermore, there
is mounting evidence that certain procedures may be performed more safely with anticoagulation uninterrupted.13,14
Importantly, there is less experience with uninterrupted,
direct-acting OACs in this setting.15,16 The risks of bridging likely highlight the challenges in managing patients on
OAC in the periprocedural period. In the patient receiving
bridging agents, both of the most common drugs (UFH and
LMWH) require attention to dosing to prevent bleeding and
to provide anticoagulant effect (UFH on a continuous basis;
LMWH with changes in weight, kidney function, or in pregnancy). Additionally, many patients require transitions in
anticoagulants at the same time they are experiencing a transition in care (eg, on admission, from the intensive care unit
to the floor, or during discharge to another facility or home).
Such circumstances likely contribute to an increased risk
associated with the use of short-term anticoagulants. Close
attention to anticoagulant transitions and dosing is vital to
minimizing risk.17 Properly identifying the group of patients,
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if any, in whom the risk of these pitfalls is outweighed by
the benefit of OAC interruption and bridging remains a challenge. They are likely to include patients at extremely high
risk of periprocedural thromboembolic events (eg, those with
mechanical mitral valve prostheses) undergoing procedures
for which uninterrupted, periprocedural anticoagulation is
prohibitively dangerous (eg, neurological procedures).
Some have speculated that, in patients at lower risk of bleeding, bridging may be worthwhile.11 However, in our cohort
of AF patients, most of whom had low-risk Anticoagulation
and Risk Factors in Atrial Fibrillation (ATRIA) bleeding
scores, we found that bridging anticoagulation was still significantly associated with worse clinical events at 30 days,
particularly bleeding and bleeding hospitalizations. This said,
the results here are observational, and we cannot rule out the
beneficial role of bridging in select circumstances. The ongoing Effectiveness of Bridging Anticoagulation for Surgery
(BRIDGE) study, which randomized nearly 2500 warfarintreated patients undergoing surgery to either LMWH or placebo during the perioperative period, will provide additional
insight (http://www.clinicaltrials.gov; NCT00786474).
Importantly, we also observed the use of bridging anticoagulation in patients receiving the oral direct thrombin inhibitor
dabigatran. Although guidelines on the use of novel OACs in
the setting of procedures are limited,18 their pharmacokinetics are such that bridging is likely redundant (although this
remains to be proven in patients at high risk of thromboembolic events). In contrast to warfarin, which requires several
days both to take effect and to wash out, direct-acting anticoagulants demonstrate short time to onset and are cleared relatively quickly, similar to LMWHs. Thus, the use of bridging
anticoagulants in such patients has been cautioned; however,
additional studies are needed.9

Limitations
This analysis is derived from the ORBIT-AF registry, which
is an observational study of real-world patients in community,
clinical practice. Limitations of such a study include enrollment or sampling biases and reporting bias. Because patients
were not randomized either to the occurrence of an interruption or to the use of bridging, a causal relationship between
these events and adverse outcomes cannot be confirmed.
Furthermore, it is possible that postprocedure parenteral anticoagulation is a requirement of the procedure; thus, use of
such an agent would occur regardless of whether a patient is
on long-term OAC. Data for patients who undergo procedures
without interruption and for those who interrupt anticoagulation for reasons other than procedures are not available; thus,
we cannot comment on the implications of our findings for
these groups. Finally, despite statistical methods aimed at
adjusting for baseline differences in the population, we cannot
exclude residual or unmeasured confounding of the results.

Conclusions
Temporary interruptions are common in patients receiving
OAC for AF and occur even for minimally invasive procedures. Many patients receive bridging anticoagulation, and its
use varies by procedure type and certain patient characteristics. Use of bridging anticoagulation was associated with an

increased risk of bleeding and adverse events after interruption. These data do not support the use of routine bridging
in anticoagulated patients with AF, and additional data are
needed to identify best practices concerning anticoagulation
interruptions.
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Clinical Perspective
Patients receiving oral anticoagulation often require temporary interruption of such therapy for invasive procedures. Often,
bridging with short-acting anticoagulants is used; however, the safety and effectiveness of such an approach have not been
proven. We assessed the association between bridging anticoagulation and clinical outcomes in patients with atrial fibrillation receiving anticoagulation that was temporarily interrupted for a procedure. Among 7372 community outpatients in the
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry treated with oral anticoagulation at baseline, 2803 overall interruption events occurred in 2200 patients (30%) at a median follow-up of 2 years. Bridging
anticoagulants were used in 24% (n=665), most commonly with low-molecular-weight heparin (73%, n=487) and unfractionated heparin (15%, n=97). After adjustment for known confounders, bleeding events were more common in bridged than
nonbridged patients (5.0% versus 1.3%; adjusted odds ratio, 3.84; P<0.0001). The incidence of myocardial infarction, stroke
or systemic embolism, major bleeding, hospitalization, or death within 30 days was also significantly higher in patients
receiving bridging (13% versus 6.3%; adjusted odds ratio, 1.94; P=0.0001). These data call into question the safety of routinely bridging patients on oral anticoagulation who require temporary interruption for a procedure. Additional prospective
trials are necessary to identify in which patients, if any, the benefit of bridging outweighs the risk.
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